Home Current Archive Editorial Team
About us
Aims and scope About Author Guidelines
News Contact
×
Home Current Archive Editorial board

Aims and scope About Author Guidelines
News Contact
Review paper
Received: 05.07.2017. >> Accepted: 09.07.2017. >> Published: 01.08.2017. Biochemistry
<< Prev | Next >>
PDF
https://doi.org/10.17392/920-17

Importance of inflammatory markers and IL-6 for diagnosis and follow up of patients with type 2 diabetes mellitus

By
Maja Malenica Orcid logo ,
Maja Malenica
Contact Maja Malenica

Department for Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar
Mira Šilar ,
Mira Šilar

University Clinic of Pulmonary and Allergic Diseases, Golnik, Slovenia

View authors publications

Search this author on:

PubMed | Google Scholar
Tanja Dujić ,
Tanja Dujić

Department for Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar
Tamer Bego ,
Tamer Bego

Department for Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar
Sabina Semiz ,
Sabina Semiz

Department for Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Faculty of Engineering and Natural Sciences, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Sarajevo, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar
Selma Škrbo ,
Selma Škrbo

Department for Clinical Pharmacy, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar
Besim Prnjavorac ,
Besim Prnjavorac

General Hospital, Tešanj, Tešanj, Bosnia and Herzegovina

Department for Pathophysiology, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar
Adlija Čaušević
Adlija Čaušević

Department for Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar

Abstract

Aim
To analyse the long-term impact of altered metabolism on the level of mediators of inflammatory response in female patients with type 2 diabetes.
Methods
This study included 97 female patients with type 2 diabetes and 107 female, nondiabetic control subjects, who were recruited at the Clinical Centre University of Sarajevo and the General Hospital Tešanj. The effects of glycaemic control on markers of inflammatory response represented by C-reactive protein (CRP), fibrinogen, leukocytes, sedimentation rate, and cytokine IL-6 were tested. All subjects were free of evidence of infections, surgery, thyroid disease, polycystic ovarian syndrome, active liver and kidney damage. All biochemical analyses were performed according to standard International Federation of Clinical Chemistry (IFCC) protocols.
Results
 A significant increase of fibrinogen (p<0.001), CRP (p=0.001), interleukin-6 (p=0.013), leukocytes (p<0.001) and sedimentation rate (p=0.008) in diabetic female population compared to control subjects was found. A significant correlation between CRP and haemoglobin A 1c (p=0.035), interleukin-6 and glucose (p=0.032), IL-6 and body mass index (p=0.007) was found.
Conclusion
 Our data suggest that inflammation plays an important role in the pathogenesis of diabetes in female diabetic population. A more detailed study on a far larger number of subjects is needed if they were to be used effectively as biomarkers in the primary prevention of type 2 diabetes in this population.

Keywords:

inflammation,
cytokine,
hyperglycaemia

References

1.
Nolan C, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011. p. 169–81.
2.
Dall T, Narayan K, Gillespie K, Gallo P, Blanchard T, Solcan M, et al. Detecting type 2 diabetes and prediabetes among asymptomatic adults in the United States: modeling American Diabetes Association versus US Preventive Services Task Force diabetes screening guidelines. Popul Health Metr. 2014. p. 12.
3.
Global report on diabetes. Diabetes country profiles. WHO; 2016.
4.
Roche M, Wang P. Factors associated with a diabetes diagnosis and late diabetes diagnosis for males and females. J Clin Transl Endocrinol. 2014. p. 77–84.
5.
Herder C, Carstensen M, Ouwens D. Anti-inflammatory cytokines and risk of type 2 diabetes. Diabetes Obes Metab. 2013. p. 39–50.
6.
Thorand B, Baumert J, Kolb H, Meisinger C, Chambless L, Koenig W, et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results fromthe MONICA/KORA Augsburg case-cohort study. Diabetes Care. 1984. p. 854–60.
7.
Meisinger C, Thorand B, Schneider A, Stieber J, Doring A, Lowel H. Sex differences in risk factors for incident type 2 diabetes mellitus: the MONI-CA Augsburg cohort study. Arch Intern Med. 2002. p. 82–9.
8.
Thorand B, Baumert J, Doring A, Herder C, Kolb H, Rathmann W, et al. Sex differencesin the relation of body composition to markers of inflammation. Atherosclerosis. 2006. p. 216–24.
9.
Hu F, Meigs J, Li T, Rifai N, Manson J. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004. p. 693–700.
10.
Qi L, Rifai N, Hu F. Interleukin-6 receptor gene, plasma C-reactive protein, and diabetes risk in women. Diabetes. 2009. p. 275–8.
11.
Bo M, Raspo S, Morra F, Cassader M, Isaia G, Poli L. Body fat is the main predictor of fibrinogen levels in healthy non-obese men. Metabolism. 2004. p. 984–8.
12.
Dessert J, Bocquet P, Belleville J, Later R, Quincy. An automated immuno-nephelometric method for the quantitative determination of plasma fibrinogen. p. 215–22.
13.
Human IL-6 Flex Set. 2AD.
14.
Grossmann V, Schmitt V, Zeller T, Panova-Noeva M, Schulz A, Laubert-Reh D, et al. Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diabetes Care. 2015. p. 1356–64.
15.
Mirza S, Hossain M, Mathews C, Martinez P, Pino P, Gay J, et al. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine. 2012. p. 136–42.
16.
Pickup J. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004. p. 813–23.
17.
Donath M, Shoelson S. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011. p. 98–107.
18.
Wang X, Liu B, Ouyang J, Wang Y, Rong D, S, et al. Inflammatory markers andrisk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2013. p. 166–75.
19.
Han T, Sattar N, Williams K, Gonzalez-Villalpando C, Lean M, Haffner S. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002. p. 2016–21.
20.
Dehghan A, Kardys I, De Maat M, Uitterlinden A, Sijbrands E, Bootsma A, et al. Genetic variation, Creactive protein levels, and incidence of diabetes. Diabetes. 2007. p. 872–8.
21.
Lee C, Adler A, Sandhu M, Sharp S, Forouhi N, Erqou S, et al. Wareham NJ. Association of C-reactive protein with type 2 diabetes: prospective analysis and metaanalysis. Diabetologia. 2009. p. 1040–7.
22.
Donath M. Inflammation as a sensor of metabolic stress in obesity and type 2 diabetes. Endocrinology. 2011. p. 4005–6.
23.
Kristiansen O, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes. 2005. p. S114-124.
24.
Pradhan A, Manson J, Rifai N, Buring J, Ridker P. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001. p. 327–34.
25.
Ford E. Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am J Epidemiol. 2002. p. 57–64.
26.
Lindsay R, Krakoff J, Hanson R, Bennett P, Knowler W. Gamma globulin levels predict type 2 diabetes in the Pima Indian population. Diabetes. 2001. p. 1598–603.
27.
Vozarova B, Weyer C, Lindsay R, Pratley R, Bogardus C, Tataranni P. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002. p. 455–61.
28.
Twig G, Afek A, Shamiss A, Derazne E, Tzur D, Gordon B, et al. White blood cells count and incidence of type 2 diabetes in young men. Diabetes Care. 2013. p. 276–82.
29.
Popko K, Gorska E, Stelmaszczyk-Emmel A, Plywaczewski R, Stoklosa A, Gorecka D, et al. Proinflammatory cytokines Il-6 and TNF-alpha and the development of inflammation in obese subjects. Eur J Med Res. 2010. p. 120–2.
30.
Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004. p. 4–7.
31.
Klein S. Is visceral fat responsible for the metabolic abnormalities associated with obesity?: implications of omentectomy. Diabetes Care. 2010. p. 1693–4.
32.
Jung U, Choi M. Obesity and its metabolic com.

Citation

Copyright

Authors retain copyright. This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

 

Article metrics

Google scholar: See link

{{ submission.title }}
Issue image
Vol 14, Issue 2, 2017
Cytotoxic and genotoxic studies of essential oil from Rosa damascene Mill., Kashan, Iran Significance of parathyroid scintigraphy and correlation of findings with parathyroid hormone values in patients undergoing hemodialysis The effect of functional insulin therapy on glycaemic parameters in children with diabetes mellitus type 1 Importance of inflammatory markers and IL-6 for diagnosis and follow up of patients with type 2 diabetes mellitus Metformin use associated with lower risk of cancer in patients with diabetes mellitus type 2 See full issue

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.